Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Levetiracetam for cerebellar tremor in multiple sclerosis: an open-label pilot tolerability and efficacy study.

Striano P, Coppola A, Vacca G, Zara F, Brescia Morra V, Orefice G, Striano S.

J Neurol. 2006 Jun;253(6):762-6. Epub 2006 May 12.

PMID:
16683063
2.

Activity, tolerability and efficacy of levetiracetam on cerebellar symptoms in multiple sclerosis patients: a pilot kinematic study.

Solaro C, Brichetto G, Capello E, Abuarqub S, Sanguineti V.

Eur J Neurol. 2008 Jun;15(6):619-26. doi: 10.1111/j.1468-1331.2008.02129.x.

PMID:
18474077
3.
4.

An open-label pilot study of levetiracetam for essential tremor.

Ondo WG, Jimenez JE, Vuong KD, Jankovic J.

Clin Neuropharmacol. 2004 Nov-Dec;27(6):274-7.

PMID:
15613931
5.

Effects of levetiracetam on chronic pain in multiple sclerosis: results of a pilot, randomized, placebo-controlled study.

Rossi S, Mataluni G, Codecà C, Fiore S, Buttari F, Musella A, Castelli M, Bernardi G, Centonze D.

Eur J Neurol. 2009 Mar;16(3):360-6. doi: 10.1111/j.1468-1331.2008.02496.x.

PMID:
19364364
7.

Open-label pilot study of levetiracetam (Keppra) for the treatment of chorea in Huntington's disease.

Zesiewicz TA, Sullivan KL, Hauser RA, Sanchez-Ramos J.

Mov Disord. 2006 Nov;21(11):1998-2001.

PMID:
16941461
8.

The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis.

Feys P, D'hooghe MB, Nagels G, Helsen WF.

Mult Scler. 2009 Mar;15(3):371-8. doi: 10.1177/1352458508099142. Epub 2009 Jan 23.

PMID:
19168602
9.

The efficacy of primidone in reducing severe cerebellar tremors in patients with multiple sclerosis.

Naderi F, Javadi SA, Motamedi M, Sahraian MA.

Clin Neuropharmacol. 2012 Sep-Oct;35(5):224-6. doi: 10.1097/WNF.0b013e31826249bb.

PMID:
22821064
10.

[Effectiveness and safety of levetiracetam in patients with essential tremor: data from an open 11-week follow-up trial].

Sanz-Cartagena P, Fossas P, Floriach-Robert M, Serra-Prat M, Cano A, Palomeras E.

Rev Neurol. 2007 Aug 1-15;45(3):134-6. Spanish.

11.

Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial.

Glauser TA, Pellock JM, Bebin EM, Fountain NB, Ritter FJ, Jensen CM, Shields WD.

Epilepsia. 2002 May;43(5):518-24.

12.

Efficacy of levetiracetam in Huntington disease.

de Tommaso M, Di Fruscolo O, Sciruicchio V, Specchio N, Cormio C, De Caro MF, Livrea P.

Clin Neuropharmacol. 2005 Nov-Dec;28(6):280-4.

PMID:
16340384
13.
14.
15.

Levetiracetam is not effective for essential tremor.

Elble RJ, Lyons KE, Pahwa R.

Clin Neuropharmacol. 2007 Nov-Dec;30(6):350-6.

PMID:
18090460
16.

Levetiracetam in patients with cortical myoclonus: a clinical and electrophysiological study.

Striano P, Manganelli F, Boccella P, Perretti A, Striano S.

Mov Disord. 2005 Dec;20(12):1610-4.

PMID:
16078205
18.

The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy.

Steinhoff BJ, Somerville ER, Van Paesschen W, Ryvlin P, Schelstraete I.

Epilepsy Res. 2007 Aug;76(1):6-14. Epub 2007 Aug 6.

PMID:
17681453
19.

Levetiracetam versus carbamazepine in patients with late poststroke seizures: a multicenter prospective randomized open-label study (EpIC Project).

Consoli D, Bosco D, Postorino P, Galati F, Plastino M, Perticoni GF, Ottonello GA, Passarella B, Ricci S, Neri G, Toni D; EPIC Study.

Cerebrovasc Dis. 2012;34(4):282-9. doi: 10.1159/000342669. Epub 2012 Nov 1.

20.

Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study.

Chung S, Ceja H, Gawłowicz J, Avakyan G, McShea C, Schiemann J, Lu S.

Epilepsy Res. 2012 Aug;101(1-2):92-102. doi: 10.1016/j.eplepsyres.2012.03.007. Epub 2012 Apr 18.

PMID:
22516508

Supplemental Content

Support Center